Please upgrade your browser.
A panel of cancer experts will discuss the efficacy and safety of Tivozanib and then vote for or against approval. In most cases, the FDA follows the recommendation of the ODAC panel.
Researchers with UCLA's Institute of Urologic Oncology and department of urology have classified kidney cancer into several unique subtypes, a breakthrough that will help physicians tailor treatment to individual kidney cancer patients, moving cancer care one step closer to personalized medicine.
A live video feed from the aftermath of the explosions at today's Boston Marathon.
The AACR Annual Meeting once again highlighted the latest and most exciting discoveries in every area of cancer research and provide a unique opportunity for investigators from all over the world to meet and forge collaborations. Following are some meeting highlights specific to renal cancers.
In a study published in the journal Science Translational Medicine, the researchers detail how low doses of the drug interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD), a debilitating condition that often occurs in patients who have received a stem cell transplant. In patients with chronic GVHD, donor immune cells launch an attack on healthy tissue. IL-2 is so versatile at restoring immune system balance, the researchers found, that it may eventually become a primary treatment for chronic GVHD and may even hold promise for treating autoimmune diseases, such as rheumatoid arthritis and lupus, which result from a misguided immune system attack on otherwise healthy organs and tissues.
Functioning kidney built from newborn rat cells is a major step towards personalised transplant organs for people.
M. D. Anderson annual Kidney Cancer Association Patient & Survivor Conference, Houston, Texas
The nonprofit Association of Cancer Online Resources (www.acor.org) cancer email lists are apparently being abandoned in favor of a new for-profit business model.
New website offers kidney cancer survivors the opportunity to share stories about their cancer journey, while connecting with others on an interactive map of the world.
Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.
|Powered by NeonCRM|